Quantum Biopharma (NASDAQ:QNTM – Get Free Report) and Marker Therapeutics (NASDAQ:MRKR – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk and dividends.
Profitability
This table compares Quantum Biopharma and Marker Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Quantum Biopharma | N/A | -84.21% | -62.63% |
| Marker Therapeutics | -179.74% | -89.63% | -71.62% |
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Quantum Biopharma and Marker Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Quantum Biopharma | 0 | 0 | 0 | 0 | 0.00 |
| Marker Therapeutics | 0 | 0 | 2 | 2 | 3.50 |
Institutional & Insider Ownership
1.2% of Quantum Biopharma shares are held by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are held by institutional investors. 8.5% of Quantum Biopharma shares are held by company insiders. Comparatively, 14.5% of Marker Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Risk & Volatility
Quantum Biopharma has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500. Comparatively, Marker Therapeutics has a beta of 1.44, suggesting that its stock price is 44% more volatile than the S&P 500.
Earnings & Valuation
This table compares Quantum Biopharma and Marker Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Quantum Biopharma | N/A | N/A | -$17.90 million | ($15.98) | -0.95 |
| Marker Therapeutics | $6.59 million | 2.95 | -$8.24 million | ($1.33) | -1.29 |
Marker Therapeutics has higher revenue and earnings than Quantum Biopharma. Marker Therapeutics is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks.
Summary
Marker Therapeutics beats Quantum Biopharma on 10 of the 14 factors compared between the two stocks.
About Quantum Biopharma
Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.
About Marker Therapeutics
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.
Receive News & Ratings for Quantum Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quantum Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
